2021年中国penA-60.001淋病奈瑟菌临床分离株的抗菌药物耐药性分析与基因组分析
对2021年在中国首次采集的463株淋病奈瑟菌进行琼脂稀释法和全基因组测序分析,发现对青霉素、四环素、环丙沙星、头孢曲松、头孢克肟和阿奇霉素的高耐药率。所有penA-60.001克隆均对头孢曲松或头孢克肟耐药,12例中1例对阿奇霉素耐药。penA-60.001亚克隆的持续传播可能进一步威胁治疗效果。
要点
- 463株淋病奈瑟菌对环丙沙星耐药率98.3%、四环素87.9%、青霉素75.2%。
- 对头孢曲松耐药率8.9%、头孢克肟14.3%、阿奇霉素8.6%。
- 所有penA-60.001克隆均对头孢曲松或头孢克肟耐药,12例中1例对阿奇霉素耐药。
核心结论
- 结果首次证明2021年中国淋病奈瑟菌存在极其严重的抗菌药物耐药率,尤其是头孢曲松敏感性降低的菌株。
- penA-60.001亚克隆的持续传播可能进一步威胁治疗效果。
研究设计与样本
- 采用琼脂稀释法和全基因组测序分析2021年在中国首次采集的463株淋病奈瑟菌的抗菌药物耐药性。
主要发现
- 463株分离株对青霉素耐药率75.2%、四环素87.9%、环丙沙星98.3%、头孢曲松8.9%、头孢克肟14.3%、阿奇霉素8.6%。
- 所有penA-60.001克隆均对头孢曲松或头孢克肟耐药,12例中1例对阿奇霉素耐药。
- penA-60.001分离株的主要基因型为MLST-7365(n=5)和MLST-1903(n=3),其余4株分别为MLST-10314、MLST-13871、MLST-7827和MLST-1600。
- 多数penA-60.001菌株与全球FC428相关克隆完全混合;2021-A2与F89同源;2021-A1呈现独特进化轨迹。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neisseria gonorrhoeae antimicrobial resistance (AMR) is an urgent public health threat. With dissemination of FC428-related clones, the efficacy of ceftriaxone has become controversial. METHODS: Agar dilution and whole genome sequencing were used to analyze AMR. RESULTS: High resistance to penicillin (75.2%), tetracycline (87.9%), ciprofloxacin (98.3%), ceftriaxone (8.9%), cefixime (14.3%), and azithromycin (8.6%) was observed among 463 isolates first collected in China in 2021. All penA-60.001 clones exhibited resistance to ceftriaxone or cefixime, and 1 of the 12 cases was resistant to azithromycin. ngMAST and ngSTAR of penA-60.001 isolates showed that single-nucleotide polymorphisms in the porB, tbpB, ponA, gyrA, and parC genes were the major causes of different sequence types. MLST-7365 (n = 5) and MLST-1903 (n = 3) were main genotypes, and the other 4 strains featured MLST-10314, MLST-13871, MLST-7827 and MLST-1600. Furthermore, resistance markers (eg, penA, blaTEM-1, blaTEM-135) and virus factors were detected. Most penA-60.001 strains were fully mixed with global FC428-related clones; 2021-A2 and F89 had the same origin; and 2021-A1 exhibited a unique evolutionary trajectory. CONCLUSIONS: Results provide the first demonstration of extremely severe AMR rates of N gonorrhoeae in China in 2021, particularly strains with ceftriaxone decreased susceptibility. The sustained transmission of penA-60.001 subclones might further threaten treatment effectiveness.
引用
- Tang Y, Liu X, Chen W, et al. Antimicrobial Resistance Profiling and Genome Analysis of the penA-60.001 Neisseria gonorrhoeae Clinical Isolates in China in 2021. J Infect Dis. 2023. PMID: 37462263. doi:10.1093/infdis/jiad258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。